ABSTRACT. We studied the effect of iopanoic acid (IOP), an iodinated contrast medium, on iodothyronine 5'4eio-dinase (5'D) and nuclear T3 content (nT3) in fetal tissues. In 18-and 20 day-old fetuses from control dams, nT3 was higher in interscapular brown adipose tissue (IBAT, 69 + 5 and 281 f 8 fmollmg of DNA) than in brain (16 f 2 and 42 f 3 fmollmg of DNA) or liver (5.6 2 1 and 27 f 2 fmol/mg of DNA). IOP administration (10 mg, twice daily) to pregnant rats on days 18 and 19 postconception significantly blocked 5'D activity in fetal IBAT and brain at day 20. Liver 5'D was not affected. The rise in nT3 was not modified by IOP treatment in IBAT, but it was enhanced in brain and liver of IOP-treated fetuses on day 20. In contrast, in adult rats, IOP treatment reduced IBAT nTa. Prolongation of IOP treatment until day 21 decreased fetal body weight on day 22 and inhibited IBAT 5'D. No change was produced in mitochondrial oxidative capacity, the subunit I1 of cytochrome oxidase, or uncoupling protein mRNA expression in IBAT from IOP-treated fetuses. Thus, the finding that IOP does not decrease the nT3 of fetal IBAT explains the lack of effect of IOP on uncoupling protein expression in fetuses, in contrast with the known decrease in adults. Present results also show that IOP increases nT3 in brain and liver, indicating a general incapacity of IOP to decrease nT3 in fetal tissues. It is concluded that the effects of IOP during fetal life differ from those in adults. (Pediatr Rcs 35: [91][92][93][94][95]1994 Supported by grant PB89-0227 from the Spanish Ministry of Education and Science and from the CIRIT (Generalitat de Catalunya, Spain). Alex Tuca is supported by a fellowship from the Generalitat de Catalunya (Spain).
A large proportion of the T3 produced in humans and in rats is generated by 5'-deiodination (5'D) of T4 in peripheral tissues (1). Two types of enzymatic system catalyzing 5'D have been described. Type I and type I1 5'-deiodinases (5'D-I and 5'D-11) differ in catalytic residues, reaction kinetics, substrate and inhibitor specificities, tissue distribution and ontogenic profiles (2-9). 5'D-I is most abundant in liver and kidney, but is detectable in other tissues (4,s). 5'D-I1 is present mainly in the brain, pituitary and BAT (5, 6). Interestingly, tissues expressing 5'D-I and 5'D-I1 differ in their dependence on T3 or T4 in plasma for intracellular T3. IOP, a cholecystographic contrast agent, is an inhibitor of 5'D (lo), and has been used to demonstrate the importance of local T4-to-T3 conversion in tissues expressing 5'D-11, such as pituitary (1 1), brain (12) and BAT (1 3).
BAT is the main site for nonshivering adaptative thermogenesis, and it has a high mitochondrial oxidative capacity and a unique mitochondrial UCP that causes dissipation of the energy of metabolic oxidation as heat (14) . BAT must be fully differentiated at birth, as its thermogenic activity is especially important during the neonatal period (15). The onset of UCP gene transcription, which may be considered as the key point of brown fat differentiation in vivo, begins between days 18 and 19 of fetal life in the rat, and is followed by an abrupt increase in UCP mRNA levels (16, 17) . BAT S'D-I1 shows peak values on day 20 of fetal life (18), in parallel to the maturation of nuclear T3 receptor expression and T3 receptor occupancy, for which maximum values are also reached in IBAT at day 20 (17) . In adult brown fat, UCP expression is highly dependent on local T3 generation by 5'D-I1 because its blockade by IOP impairs UCP expression in response to cold stress (19). ow ever, IOP administration to pregnant rats does not affect the rise in UCP expression in fetal IBAT (16). These discrepancies prompted us to reevaluate the effects of IOP administration to pregnant mothers on the thyroidal status of fetal tissues. In the present report, we determine the effect of IOP treatment from day 18 of gestation (onset of active thyroid function in the fetus) on the rise of 5'D activity and nuclear T3 content in IBAT, brain, and liver between days 18 and 20 of fetal life. The effects of IOP treatment on the functionality of IBAT from fetuses at term have also been studied.
MATERIALS AND METHODS

Animals.
Wistar rats from our breeding colony initially weighing 180-200 g were used. They were fed with a stock diet (A03 type, Panlab, Spain) and kept in a controlled environment (1 2-h lightidark cycles, 2 lac, 85% humidity). They were maintained and treated in accordance with international recommendations for the care and use of laboratory animals. Female rats were mated and the day of pregnancy was determined by the presence of spermatozoa in vaginal smears. The administration of IOP was started at day 18 of gestation. Caesarean sections were performed at 18 (only untreated animals), 20 and 22 days of gestation. Fetuses were killed by decapitation, and IBAT, brain, and liver were removed. Tissue samples were immediately frozen in liquid nitrogen with the exception of brown fat from several 22day-old fetuses, which was directly homogenized in 0.25 M sucrose for mitochondria isolation (20).
IOP treatment. IOP (Telepaque) was supplied by Sterwin Espaiiola. IOP solution (250 mgl12.5 mL) was prepared daily. IOP was dissolved in 0.05 N NaOH and pH was lowered to 7.5-7.8 by addition of 0.2 N HCl. Pregnant rats were injected subcutaneously with 10 mg of IOP every 12 h, from day 18 of gestation to 12 h before they were killed on the morning of day 20 or 22 of gestation. Control animals received the vehicle solution with identical timing. IOP effectiveness in decreasing IBAT nuclear T3 was assessed by IOP administration to adult male rats (220-250 g body weight) following the same dose and time schedule as in pregnant dams during two days.
Iodothyronine 5'-deiodinase assays. Outer ring 5'-deiodinating activity was assayed by quantifying the '251-liberated from rT3 as described previously (9). Briefly, liver 5'D-I was assayed at a final concentration of 0.5 pM rT3 and 1 mM DTT (Calbiochem), whereas IBAT 5'D-I1 and brain 5'-D activities were determined in the presence of 2 nM rT3 and 20 mM DTT. Brain 5'D-I1 was measured by the addition of 1 mM PTU (12). Incubations were performed at 37°C for 5 min (liver) or 60 min (brown adipose tissue and brain). Separation of iodine from iodothyronines was canied out by ion-exchange chromatography on Dowex 50W-X2 column (Bio-Rad) equilibrated with 10% acetic acid. The enzyme levels in liver are expressed as pmol I-. h-' mg protein-' whereas in BAT and brain they are expressed
Determination of nuclear T3 content. Nuclei were isolated as described previously (17). Briefly, frozen tissues were homogenized in 10 vol/g of tissue buffer A (0.32 M sucrose, 1 mM CaC12, 2 mM MgC12, 0.1 % Triton X-100, 1 mM DTT, 0.1 mM PMSF, and 10 mM Tris, pH 7.5). The homogenates were filtered through four layers of nylon mesh and centrifuged at 4000 X g for 10 min. The crude nuclear pellets were resuspended in 0.5 mL of buffer A, mixed with 4.5 mL of buffer B (2 M sucrose, 1 mM CaC12, 2 mM MgC12, 1 mM DTT, 0.1 mM PMSF, and 10 mM Tris, pH 7.3, and centrifuged at 100,000 x g for 60 min. The nuclear pellets were washed and resuspended in buffer C (0.32 M sucrose, 1 mM CaC12, 2 mM MgC12, 1 mM DTT, 0.1 mM PMSF, and 10 mM Tris, pH 7.5) at 2 g of starting tissue per milliliter. Recovery of DNA in the final nuclear pellets ranged from 50-60 percent. Nuclear T3 was extracted essentially as described by Hartong et al. (21) . Aliquots of isolated nuclei resuspended in buffer C were extracted three times with 4 volumes of 99% ethanol. Parallel studies using nuclei prelabeled with '251T~ in vivo indicated that this procedure resulted in extraction of more than 85% of the nuclear labeled T3. The combined ethanolic extracts were then dried by rotatory evaporation (Speed-Vac), and the residues were resuspended in the assay buffer. T3 radioimmunoassay was performed as described elsewhere ( l7,22) using antibodies from Henning (Berlin) and free acid L-T3 (Sigma) as reference. Resuspended samples were assayed in triplicate. Two further aliquots were used to determine the individual nonspecific binding occurring in the absence of specific antibody. Correction of total binding for nonspecific binding was performed for each individual sample. Displacements with different dilutions of the samples were essentially parallel to those obtained for the standard curve in buffer. RNA isolation and Northern analysis. Total RNA was prepared from frozen brown adipose tissue by homogenization in 4 M guanidine thiocyanate (23). RNA samples (10 pg per lane), containing 0.2 pg/mL ethidium bromide for easy monitoring of the RNA (24) , were subjected to electrophoresis on 1.5% agarose, 2 M formaldehyde gels. After fixation to nylon filters (Hybond N, Amersham), RNA was hybridized to the pUCP36 insert, containing full-length cDNA for the rat UCP (25) , or to the 0.5-kb pIL-7 insert corresponding to part of the c-DNA for COII (26) . The cDNA probes were labeled using [cI-~~PI~CTP (Amersham) by the random oligonucleotide-priming method. Filters were washed under stringent conditions (30 mM NaCl, 3 mM sodium citrate, 0.1 % SDS, 65"C, 30 min). For quantification, autoradiographs were scanned using a densitometer (LKB).
Synthesis of labeled tracers. High specific radioactivity [5'-'ZSI] rT3 and [5'-'251]T3 were obtained by radioiodination with I2'I-(IMS 30; Amersham) using 3,3'-diiodothyronine and 3,5-diiodothyronine (Henning) as substrate, respectively (27) .
Other determinations. DNA was determined by bisbenzimidazole (Hoechst 33258, Sigma) fluorescence (28) . Protein was determined by a modification of the Lowry method in tissue homogenates and mitochondria pellets (29) . Cytochrome oxidase activity was determined in tissue homogenates and mitochondria preparations (30) . The recovery of cytochrome oxidase in each sample was used to determine the mitochondrial protein content of brown adipose tissue. Statistical comparisons were performed by unpaired or paired t test and analysis of variance.
RESULTS
IBAT and liver 5'D activities increased significantly from day 18 to day 20 of fetal life (Fig. 1, A and C, respectively). Brain 5'D total activity (type I + type 11) did not change during this period, whereas 5'D-I1 (FTU-insensitive) increased significantly (Fig. 1B) . Nuclear T3 content was also higher in IBAT, brain, and liver from 20-day-old fetuses than from those at day 18 (Fig.  1, D, E, F) . Nuclear T3 concentrations were higher in IBAT than in brain (4-6-fold) or liver ( 10-fold) during this period. The doseresponse curve obtained with different dilutions of resuspended extracts prepared from IBAT of 20-day-old fetuses was parallel to the T3 standard curve (Fig. 2) . This result rules out the possibility that the high nuclear T3 content determined in fetal IBAT was artifactual.
IOP administration to pregnant rats during days 18 and 19 postconception did not modify litter size (controls: 1 1.8 f 0.5 fetusesldam, IOP-treated: 11.6 f 0.6 fetusesldam) or body weight at day 20 (controls: 3.27 f 0.12 g, IOP-treated: 3.42 & 0.20 g). IOP treatment produced a significant blockage of 5'D activity in IBAT and brain; in contrast, liver 5'D was not modified. T3 content was similar in IBAT and slightly increased in brain and liver nuclei of IOP-treated fetuses when compared with control fetuses at day 20 ( p < 0.05) (Fig. 1, D , E, and F, respectively). However, when administered to adult rats, IOP produced a significant reduction in IBAT nuclear T3 content and plasma T3 concentration (Table 1) .
Considering the significance of nuclear T3 content in fetal IBAT when compared with other fetal tissues at day 20 and the fact that BAT continues its differentiation during late fetal life, the question arose as to whether longer IOP treatment might affect BAT functionality in fetuses at term. In the second experiment, IOP was injected to pregnant dams from day 18 to 2 1 of gestation (i.e. 4 days instead of 2 days). This treatment produced a significant decrease in the body weight of 22-day old fetuses ( Table 2 ). The litter size was not modified (data not shown). IOP inhibition of IBAT 5'D activity in fetuses at term was as effective as at day 20. The nuclear T3 content in this experimental series was not determined because DNA recovery in the final nuclear pellets from both treated and untreated fetuses was too low for accurate Ts determination (between 27 and 13% recovery at term and 53.5 a 4.5% at day 20). IOP treatment did not affect either UCP or COII mRNA expression or mitochondrial oxidative capacity, as assessed by mitochondrial protein content and cytochrome oxidase activity.
DISCUSSION
The present study shows that nuclear T3 content increases in IBAT, brain and liver between days 18 and 20 of gestation. Our results are in agreement with published data of T3 and T4 concentrations in fetal tissues, which also increase during this period, coinciding with the onset of active fetal thyroid function (31) (32) (33) . Interestingly, both cellular (31) and nuclear T3 levels are higher in fetal IBAT than in the other tissues. On the other hand, IBAT 5'D-I1 reaches maximal levels on day 20 of fetal life ( 18). Moreover, on day 20, the concentration of T3 binding sites is also higher in IBAT nuclei than in liver (17) or brain nuclei (34) . Taken together, these results suggest a general profile of early maturation in the thyroid hormone status of IBAT.
As to the effects of IOP administration during gestation, the low levels of 5'D activities in IBAT and brain of IOP-treated fetuses indicate that IOP crosses the placenta and reaches the fetus. In contrast, liver 5'D was not modified by IOP administration. It has been reported that, in adult rats, hepatic or renal 5'D-I are 100-fold less sensitive to IOP inhibition than S'D-I1 from pituitary gland or cerebral cortex (10). On the other hand, low sensitivity to other inhibitory agents has been described for the fetal or neonatal forms of liver 5'D (35, 36) . However, in the absence of direct data of IOP concentration in fetal tissues, we cannot rule out the possibility that the lack of effect of IOP administration on fetal liver 5'D-I may be produced by decreased transport and/or increased metabolization of IOP in fetal liver.
Our results demonstrate that IOP administration at days 18 and 19 of gestation does not block the characteristic rise in T3 levels in IBAT nuclei during this period, despite the high sensitivity of IBAT S'D-I1 to inhibition by IOP. Previous reports have described that the pattern of UCP expression during fetal development is not modified in fetuses from IOP-treated dams (16). The present results further extend these studies by showing that neither mitochondrial oxidative capacity nor UCP or COII 
